IL144003A0 - Compounds and methods for modulation of estrogen receptors - Google Patents
Compounds and methods for modulation of estrogen receptorsInfo
- Publication number
- IL144003A0 IL144003A0 IL14400399A IL14400399A IL144003A0 IL 144003 A0 IL144003 A0 IL 144003A0 IL 14400399 A IL14400399 A IL 14400399A IL 14400399 A IL14400399 A IL 14400399A IL 144003 A0 IL144003 A0 IL 144003A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- disclosed
- compounds
- same
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11447298P | 1998-12-30 | 1998-12-30 | |
PCT/US1999/031290 WO2000039120A2 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144003A0 true IL144003A0 (en) | 2002-04-21 |
Family
ID=22355427
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14400399A IL144003A0 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
IL144003A IL144003A (en) | 1998-12-30 | 2001-06-26 | History of 3 - phenyl - 4 - [(heterocyclic) ethoxy] - benzyl - coumarin - 7 - metamorphoses and pharmaceutical preparations containing these compounds to regulate estrogen receptors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL144003A IL144003A (en) | 1998-12-30 | 2001-06-26 | History of 3 - phenyl - 4 - [(heterocyclic) ethoxy] - benzyl - coumarin - 7 - metamorphoses and pharmaceutical preparations containing these compounds to regulate estrogen receptors |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1140889B1 (xx) |
JP (1) | JP2002533456A (xx) |
KR (1) | KR100615757B1 (xx) |
CN (2) | CN100339374C (xx) |
AT (1) | ATE248157T1 (xx) |
AU (1) | AU765159B2 (xx) |
CA (1) | CA2356986A1 (xx) |
DE (1) | DE69910830T2 (xx) |
DK (1) | DK1140889T3 (xx) |
ES (1) | ES2207982T3 (xx) |
HK (2) | HK1041258B (xx) |
IL (2) | IL144003A0 (xx) |
PT (1) | PT1140889E (xx) |
WO (1) | WO2000039120A2 (xx) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6822563B2 (en) | 1997-09-22 | 2004-11-23 | Donnelly Corporation | Vehicle imaging system with accessory control |
US5877897A (en) | 1993-02-26 | 1999-03-02 | Donnelly Corporation | Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array |
US7655894B2 (en) | 1996-03-25 | 2010-02-02 | Donnelly Corporation | Vehicular image sensing system |
US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
AU766648B2 (en) | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
KR20020075388A (ko) * | 1999-12-30 | 2002-10-04 | 시그널 파머슈티컬스 인크 | 에스트로겐 수용체의 조절 화합물 및 조절 방법 |
EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
EP1281710A1 (en) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
ATE286894T1 (de) | 2001-01-24 | 2005-01-15 | Chiesi Farma Spa | 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen |
DE60108354T2 (de) * | 2001-01-24 | 2006-01-05 | Chiesi Farmaceutici S.P.A. | 2H-1-Benzopyranderivate, Verfahren zu ihrer Herstellung und deren pharmazeutische Zusammensetzungen |
JP4358515B2 (ja) * | 2001-04-10 | 2009-11-04 | タカラバイオ株式会社 | 治療剤 |
US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
MXPA04010433A (es) * | 2002-04-19 | 2005-08-19 | Signal Pharm Inc | Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos. |
EP1504276B1 (en) | 2002-05-03 | 2012-08-08 | Donnelly Corporation | Object detection system for vehicle |
US7091235B2 (en) * | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
FR2849653B1 (fr) * | 2003-01-08 | 2006-08-25 | B F B Etudes Et Rech S Experim | Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant |
BRPI0414386A (pt) | 2003-09-15 | 2006-11-21 | Signal Pharm Llc | composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição |
US7526103B2 (en) | 2004-04-15 | 2009-04-28 | Donnelly Corporation | Imaging system for vehicle |
EP1846397A1 (en) * | 2005-01-21 | 2007-10-24 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors |
EP1899316A1 (en) * | 2005-06-24 | 2008-03-19 | Signal Pharmaceuticals LLC | Benzopyranone compounds for treating cancer |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
EP1860104A1 (en) * | 2006-05-22 | 2007-11-28 | Aptanomics | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
CN101200460B (zh) * | 2007-11-19 | 2010-06-16 | 北京珅奥基医药科技有限公司 | 二氢苯并吡喃酮类化合物及其用途 |
CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
CN112426420B (zh) * | 2020-12-01 | 2021-12-28 | 浙江大学 | 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用 |
CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2857401A (en) * | 1956-12-20 | 1958-10-21 | Searle & Co | Acetylated coumarin derivatives |
DE4323409A1 (de) * | 1993-07-13 | 1995-01-19 | Boehringer Mannheim Gmbh | Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel |
CN1173819A (zh) * | 1995-02-06 | 1998-02-18 | 伊莱利利公司 | 抑制il-6作用的方法 |
JP2001502711A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―3、4―クロマン誘導体 |
ZA979644B (en) * | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
EP0937059A1 (en) * | 1996-10-28 | 1999-08-25 | Novo Nordisk A/S | NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES |
EP0937060B1 (en) * | 1996-10-28 | 2002-12-11 | Novo Nordisk A/S | Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
JP2001502705A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関係疾患または症候群の予防または治療において有用な新規なシス―3,4―クロマン誘導体 |
ATE231141T1 (de) * | 1996-10-28 | 2003-02-15 | Novo Nordisk As | (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen |
-
1999
- 1999-12-30 DE DE69910830T patent/DE69910830T2/de not_active Expired - Fee Related
- 1999-12-30 AT AT99968578T patent/ATE248157T1/de not_active IP Right Cessation
- 1999-12-30 CN CNB2004100422993A patent/CN100339374C/zh not_active Expired - Fee Related
- 1999-12-30 IL IL14400399A patent/IL144003A0/xx active IP Right Grant
- 1999-12-30 ES ES99968578T patent/ES2207982T3/es not_active Expired - Lifetime
- 1999-12-30 KR KR1020017008410A patent/KR100615757B1/ko not_active IP Right Cessation
- 1999-12-30 CN CNB998163740A patent/CN1155589C/zh not_active Expired - Fee Related
- 1999-12-30 WO PCT/US1999/031290 patent/WO2000039120A2/en active IP Right Grant
- 1999-12-30 JP JP2000591031A patent/JP2002533456A/ja active Pending
- 1999-12-30 DK DK99968578T patent/DK1140889T3/da active
- 1999-12-30 EP EP99968578A patent/EP1140889B1/en not_active Expired - Lifetime
- 1999-12-30 PT PT99968578T patent/PT1140889E/pt unknown
- 1999-12-30 CA CA002356986A patent/CA2356986A1/en not_active Abandoned
- 1999-12-30 AU AU25970/00A patent/AU765159B2/en not_active Ceased
-
2001
- 2001-06-26 IL IL144003A patent/IL144003A/en not_active IP Right Cessation
-
2002
- 2002-02-25 HK HK02101413.5A patent/HK1041258B/zh not_active IP Right Cessation
-
2005
- 2005-09-09 HK HK05107951A patent/HK1075893A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1140889A2 (en) | 2001-10-10 |
WO2000039120A2 (en) | 2000-07-06 |
CN100339374C (zh) | 2007-09-26 |
CN1597677A (zh) | 2005-03-23 |
HK1041258B (zh) | 2003-12-12 |
IL144003A (en) | 2006-07-05 |
WO2000039120A3 (en) | 2000-10-26 |
KR100615757B1 (ko) | 2006-08-25 |
CA2356986A1 (en) | 2000-07-06 |
AU765159B2 (en) | 2003-09-11 |
HK1075893A1 (en) | 2005-12-30 |
PT1140889E (pt) | 2004-01-30 |
CN1155589C (zh) | 2004-06-30 |
JP2002533456A (ja) | 2002-10-08 |
KR20010101346A (ko) | 2001-11-14 |
DE69910830D1 (de) | 2003-10-02 |
ATE248157T1 (de) | 2003-09-15 |
ES2207982T3 (es) | 2004-06-01 |
HK1041258A1 (en) | 2002-07-05 |
DE69910830T2 (de) | 2004-06-17 |
EP1140889B1 (en) | 2003-08-27 |
CN1337958A (zh) | 2002-02-27 |
AU2597000A (en) | 2000-07-31 |
DK1140889T3 (da) | 2003-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1075893A1 (en) | Compounds and methods for modulation of estrogen receptors | |
HK1058521A1 (en) | Compounds and methods for modulation of estrogen receptors | |
WO2000055137A8 (en) | Compounds and methods for modulation of estrogen receptors | |
MY115784A (en) | Estrogen agonists/antagonists | |
DE69935335D1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
Orwoll et al. | Androgen receptors in osteoblast-like cell lines | |
MY112949A (en) | Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia | |
DE69929345D1 (de) | Subtituierte isoxazole derivate als estrogen rezeptor modulatore | |
EA200300474A1 (ru) | Модуляторы рецепторов эстрогена | |
EP1009755A4 (en) | STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME | |
ATE292468T1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
Gray et al. | Interaction of androgen and 1, 25‐dihydroxyvitamin D3: Effects on normal rat bone cells | |
NO984631D0 (no) | <alfa>1-Adrenerge reseptor-antagonister | |
DK0898708T3 (da) | Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays | |
HK1044542B (zh) | 由11β-芳基-17,17-螺硫羥烷取代的類固醇 | |
Fuse et al. | Changes in cytosolic androgen receptor after administration of testosterone of androgen-dependent mouse mammary tumor (Shionogi Carcinoma) and its sublines of altered androgen dependency | |
MY137604A (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | |
Charnock-Jones et al. | Vascular endothelial growth factor and corpus luteum angiogenesis | |
Meyers | The role of hormone receptors in estrogen activity is questionable | |
DE69720620D1 (de) | 8-Substituierte B-nor-6-Thiaequilin Verbindungen als selektiven Östrogenrezeptormodulatoren | |
Scambia et al. | 343 Hormone-dependent creatine kinase (CK) in human endometrium | |
Amroch et al. | 342 Estrogen responsive creatine kinase in normal and neoplastic human breast | |
McGuire et al. | 341 Characterization of a 24K estrogen regulated protein in human breast cancer cells | |
Boyde | Stereographic visual aids | |
Ishii et al. | A NEW THERAPEUTIC STRATEGY FOR TARGETING TUMOR STROMA IN HORMONE-REFRACTORY PROSTATE CANCER CELL GROWTH UNDER ANDROGEN ABLATION THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |